Madrigal Pharmaceuticals, Inc. (MDGL) Stock: Price, Forecast & Analyst Target
Madrigal Pharmaceuticals, Inc. (MDGL) — MoonshotScore 35/100 (Weak band), calculated Nov 18, 2026. Price $396.74 (-0.34%), as of the Nov 19, 2026 trading session; market cap $9.22B. Expected results Feb 18, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 9.59× (cash as of Sep 30, 2026) · expected results Feb 18, 2027
Madrigal Pharmaceuticals, Inc. · MDGL · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Madrigal Pharmaceuticals is being reshaped by the Rezdiffra launch: patient additions now feed a rapidly expanding commercial revenue base, while launch support and research spending still leave the company unprofitable. The case depends on whether that uptake can produce durable operating cash generation before commercialization costs absorb too much of the liquidity cushion.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Madrigal Pharmaceuticals (MDGL)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Quiet.
- EPS beat 6 of the last 8 reports
- Altman Z 6.68 · Piotroski F 1
- ROE -24.8% · ROA -6.8% · current ratio 3.05
Holding back: balance-sheet strain
Helping: business quality
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 35 | Weak | |
| 36 | Weak | |
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $396.74 | |
| Change on the day | -0.34% | |
| 52-week range | $353.54–$615.00 | |
| Market capitalisation | $9.22B | — |
| Price / earnings (trailing) | 40.15 | |
| Shares traded on the day | 416.6K | |
| Beta (volatility vs the S&P 500) | -1 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Madrigal Pharmaceuticals (MDGL): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Madrigal Pharmaceuticals (MDGL), and what does it report?
Short answer · as of
Madrigal develops and commercializes therapies for liver, metabolic, and cardiovascular disorders, but its reported economics now revolve around the Rezdiffra launch.
Research dated 2026-09-13.
The practical unit of demand is a patient added to therapy; management explicitly links continued patient additions with net sales growth.
Revenue is presented through a reportable segment, so the accounts do not offer a diversified segment mix to soften product-specific changes. The income statement therefore measures commercial adoption alongside the research and selling infrastructure required to support the launch.
What do the latest results show for Madrigal Pharmaceuticals (MDGL)?
Research dated 2026-09-13.
The latest period delivered a fresh revenue high after the preceding dip, with gross profit also rising. The net and operating losses narrowed sharply, research expense declined, and selling and administrative expense continued climbing; revenue and loss were also better than consensus.
Management expects patient additions and net sales growth to continue. It also says selling and administrative spending will increase as the Endo sales force is annualized, while research spending should remain roughly level across the full year. Those statements frame the mechanism, but the reported sequence still needs to demonstrate that sales growth can outrun the commercial cost base.
Operating cash flow turned positive in the latest period after a substantial outflow previously. That reversal strengthens the latest result, though the wider series remains uneven.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $431.27M Sep 30, 2026
- Latest quarter · R&D
- $71.75M Sep 30, 2026
- Latest quarter · SG&A
- $265.71M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $55.99M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $431.27M | $71.75M | $265.71M | $55.99M |
| Jun 30, 2026 | $364.25M | $91.18M | $289.38M | −$56.31M |
| Mar 31, 2026 | $311.34M | $108.69M | $268.52M | −$92.72M |
| Dec 31, 2025 | $321.08M | $116.27M | $239.98M | −$59.61M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $431.27M Nov 3, 2026
- Latest report · revenue estimate
- $404.17M Nov 3, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 3, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 3, 2026 | $431.27M | $404.17M | $1.8300 | −$0.8631 |
| Jul 30, 2026 | $364.30M | $352.13M | −$1.9900 | −$2.6800 |
| May 6, 2026 | $311.34M | $301.05M | −$3.2500 | −$3.6100 |
| Feb 19, 2026 | $321.10M | $312.51M | −$2.5700 | $0.0400 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $287M | -$114M | -$5.08 (diluted) |
| Q4 FY2025 | $321M | -$59M | -$2.57 (diluted) |
| Q1 FY2026 | $311M | -$94M | -$3.25 (diluted) |
| Q2 FY2026 | $364M | -$58M | -$1.99 (diluted) |
What are the financial strengths and risks for Madrigal Pharmaceuticals (MDGL)?
Short answer
Cash and short-term investments were $960.97M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $120.56M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash and short-term investments exceed reported debt and total liabilities, leaving Madrigal with meaningful capacity to fund the launch and pipeline. Liquidity also increased from the preceding period, and the latest operating cash result was positive.
The cushion has nevertheless declined across the reported window, operating cash flow has swung between inflows and outflows, and losses remain persistent despite a high gross margin. Liquid resources are also modest beside the company’s market value, so the equity case rests far more on commercial execution than on balance-sheet backing.
The damaging pattern would be slower Rezdiffra uptake while selling costs remain elevated and research commitments continue. That combination would keep operating margins negative and restart sustained cash consumption.
Data-derived red flags
- Negative return on equity (-24.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 40.15 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $120.56M Sep 30, 2026
- Previous quarter · operating cash flow
- $23.33M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $120.56M | −$3.93M |
| Jun 30, 2026 | $23.33M | −$4.25M |
| Mar 31, 2026 | −$167.43M | −$3.85M |
| Dec 31, 2025 | −$133.46M | $390,000 |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Madrigal Pharmaceuticals (MDGL)?
Short answer · as of
The next earnings report is expected on Feb 18, 2027.
Research dated 2026-09-13.
Rezdiffra patient additions, sequential net sales, and selling expense belong on the same watchlist. Revenue growth matters most if incremental gross profit begins to absorb the larger commercial organization rather than merely accompanying it.
Operating cash flow should be checked across successive periods, not judged from the latest inflow alone. The scheduled report carries consensus expectations for another revenue increase and a materially narrower loss, while longer-range estimates assume a transition to profitability; progress toward that path requires sustained sales expansion without renewed cash erosion.
Research expense also deserves attention against management’s expectation for broadly stable annual spending. A material departure could change the pace at which commercial gains reach the bottom line.
How does Madrigal Pharmaceuticals compare with its peers?
Short answer
Madrigal Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Relative to a biotechnology company still awaiting commercial revenue, Madrigal already has a fast-growing sales base and a launch organization large enough to dominate operating expenses. Relative to a diversified pharmaceutical company, its reporting offers little segment-level insulation: commercial performance is concentrated in a reportable segment and closely tied to Rezdiffra adoption.
That combination creates unusual operating leverage. High gross margins allow added sales to carry substantial gross profit, yet the current research and selling structure still produces operating losses. Similar businesses may share clinical risk or launch risk; Madrigal is already confronting each at the same time.
| Company | Price | Market value | Score |
|---|---|---|---|
| $65.83 Nov 19, 2026 | $16.1B | 98 5-pillar Nov 18, 2026 | |
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $93.04 Nov 19, 2026 | $10.6B | 95 5-pillar Nov 18, 2026 | |
| $72.70 Nov 19, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 | |
| $156.23 Nov 18, 2026 | $6.35B | 64 5-pillar Nov 18, 2026 | |
| $61.43 Nov 18, 2026 | $11.9B | 58 5-pillar Nov 18, 2026 | |
| Madrigal Pharmaceuticals (MDGL) — this page | $396.74 | $9.22B | 35 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $533.00 – $962.00
- Consensus target
- $669.22
- Median target
- $670.00
Consensus record · Captured .
Measured against a quoted price of $396.74 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026
- Transactions
- 59
- Identified insiders
- 10
- Purchases
- 5
- Sales
- 37
- Other transactions
- 17
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 75.4% Period end Sep 30, 2026
- Previous quarter · ownership
- 81.6% Prior to period end Sep 30, 2026
- Reporting holders
- 462 Period end Sep 30, 2026
- Previous quarter · holders
- 441 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Baker Bros. Advisors LP | 2,143,131 |
| Janus Henderson Group Ltd. | 1,972,696 |
| Avoro Capital Advisors LLC | 1,833,333 |
| Paulson & Co. INC. | 1,491,619 |
| Blackrock, INC. | 1,239,063 |
Tracked investors
Which of the 16 named investors we follow held MDGL in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.12% | $27.03M | New position |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Madrigal Pharmaceuticals (MDGL)?
Common Questions About MDGL (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do Rezdiffra patient additions affect Madrigal revenue?
Management connects steady patient additions directly with net sales growth. Because Madrigal reports revenue through a reportable segment, that adoption flows into the consolidated sales line without a visible segment mix to dilute the effect.
Why is Madrigal still losing money as Rezdiffra sales grow?
Commercial support and research spending remain large enough to exceed gross profit. Selling and administrative expense has continued rising, and management expects the annualized Endo sales force to keep that cost line elevated.
Can Madrigal fund the Rezdiffra launch from current liquidity?
Cash and short-term investments stand above debt and total liabilities, providing substantial funding capacity. The broader cash history and uneven operating cash flow still make the pace of future consumption important.
What would show that the Rezdiffra launch is becoming self-funding?
Repeated positive operating cash flow alongside rising revenue and narrowing operating losses would provide the clearest confirmation. The latest period moved in that direction, but prior swings mean persistence matters more than an isolated inflow.
What is the MDGL stock price today?
The last price recorded for Madrigal Pharmaceuticals, Inc. (MDGL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MDGL price target?
The analyst consensus price target for Madrigal Pharmaceuticals, Inc. (MDGL), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 79 figures on this page — 1 from SEC filings and earnings calls, 70 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com